0.2072

9.05% 0.0172

After Hours: .20 -0.0072 -3.47%

Lyra Therapeutics Inc (LYRA)

Overview News Price History Option Chain Financials Discussions Forecast

Lyra Therapeutics Inc stock is traded at $0.2072, with a volume of 1.48M. It is up +9.05% in the last 24 hours and down -21.84% over the past month. Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Previous Close:

$0.19

Open:

$0.192

24h Volume:

1.48M

Relative Volume:

1.02

Market Cap:

$13.56M

Revenue:

$1.56M

Net Income/Loss:

$-62.68M

P/E Ratio:

-0.1328

EPS:

-1.56

Net Cash Flow:

$-64.35M

1W Performance:

+9.63%

1M Performance:

-21.84%

6M Performance:

-37.40%

1Y Performance:

-93.64%

1-Day Range:

$0.1863

$0.208

1-Week Range:

$0.1839

$0.208

52-Week Range:

$0.1625

$6.79

Lyra Therapeutics Inc Stock (LYRA) Company Profile

Name

Lyra Therapeutics Inc

Sector

Healthcare (1180)

Industry

Biotechnology (675)

Phone

617-373-4600

Address

480 ARSENAL WAY, WATERTOWN, MA

Employee

Twitter

@LyraTx

Next Earnings Date

2024-11-05

Latest SEC Filings

LYRA's Discussions on Twitter

Compare LYRA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYRA Lyra Therapeutics Inc	0.2072	13.56M	1.56M	-62.68M	-64.35M	-1.29
VRTX Vertex Pharmaceuticals Inc	468.13	120.56B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	750.22	82.44B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	616.55	36.87B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	253.07	32.64B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.39	28.38B	3.30B	-501.07M	1.03B	-2.1146

Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral
May-07-24	Downgrade	Jefferies	Buy → Hold
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy
Aug-31-23	Initiated	H.C. Wainwright	Buy
May-24-22	Initiated	Cantor Fitzgerald	Overweight
May-26-20	Initiated	BTIG Research	Buy
May-26-20	Initiated	BofA/Merrill	Buy
May-26-20	Initiated	Jefferies	Buy
May-26-20	Initiated	William Blair	Outperform

View All

Lyra Therapeutics Inc Stock (LYRA) Latest News

Nov 29, 2024

LYRA (Lyra Therapeutics) GF Score : 43/100 (As of Nov. 29, 2024) - GuruFocus.com

Nov 29, 2024

Nov 26, 2024

Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Price Target at $4.50 - Defense World

Nov 26, 2024

Nov 18, 2024

William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World

Nov 18, 2024

HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World

Nov 18, 2024

Nov 14, 2024

Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa

Nov 13, 2024

Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India

Nov 13, 2024